Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Macular Degeneration–Primary End Point - Concepedia

Concepedia

Publication | Closed Access

Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Macular Degeneration–Primary End Point

93

Citations

11

References

2012

Year

David M. Brown, Eric Chen, Angeline F. Mariani, James C. Major

Ocular DiseaseOphthalmologyMg Intravitreal RanibizumabExperimental OphthalmologyPharmacotherapyGlaucomaNeovascularizationMedicineSuper-dose Anti-vegf

References

	Year	Citations

Page 1